MetaVia Inc.
MTVA
Rang in aandelen
#32902
Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a... Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a clinical-stage biotechnology company with a core focus on discovering and commercializing novel pharmaceutical solutions for cardiometabolic disorders. Its leading investigational drug, DA-1241, a unique G-Protein-Coupled Receptor 119 agonist, is currently undergoing Phase 2a clinical trials for metabolic dysfunction-associated steatohepatitis (MASH). This follows the successful completion of Phase 1 trials for type 2 diabetes mellitus (T2DM), and the compound holds promise for use as both a standalone therapy and in combination treatments. Another significant asset, DA-1726, an innovative oxyntomodulin analogue that functions as a dual agonist for GLP-1 and glucagon receptors, is presently in preclinical development specifically for treating obesity. MetaVia's broader therapeutic pipeline also includes ANA001, a distinct oral niclosamide formulation intended for moderate COVID-19 patients; NB-01, designed to address painful diabetic neuropathy; NB-02, targeting cognitive impairment; and Gemcabene, for the management of dyslipidemia. The company engages in strategic partnerships, notably a licensing agreement with Pfizer Inc. for the research, development, manufacturing, and commercialization of Gemcabene. Additionally, a joint research collaboration with Dong-A ST and ImmunoForge supports the advancement of DA-1726. The entity adopted its current name, MetaVia Inc., in November 2024, transitioning from its former identity as NeuroBo Pharmaceuticals, Inc.
Aandeelprijs
$1.28
Laatst gesynchroniseerd: 2026-10-20
Marktkapitalisatie
$8.43M
Verandering (1 dag)
4.07%
Verandering (1 jaar)
-21.47%
Land
US
Handel MetaVia Inc. (MTVA)
Categorie
Healthcare
Aantal uitstaande aandelen voor MetaVia Inc. (MTVA)
Aantal uitstaande aandelen per June 2026: 5.93B
Volgens de laatste financiële rapporten en de aandelenkoers van MetaVia Inc. bedraagt het huidige aantal uitstaande aandelen 5.93B. Aan het einde van December 2023 had het bedrijf 5.07M uitstaande aandelen. Het aantal uitstaande aandelen wordt meestal beïnvloed door aandelensplitsingen en terugkoop van aandelen.
Geschiedenis van uitstaande aandelen van MetaVia Inc. (MTVA) van 2014 tot 2026
Uitstaande aandelen aan het einde van elk jaar
| Jaar | Uitstaande aandelen | Wijzigen |
|---|---|---|
| 2026 (TTM) | 5.93B | 7,547.03% |
| 2024 | 77.57M | 1,430.30% |
| 2023 | 5.07M | 1,475.68% |
| 2022 | 321.70K | 233.61% |
| 2021 | 96.43K | 42.71% |
| 2020 | 67.57K | 221.77% |
| 2019 | 21.00K | 18.56% |
| 2018 | 17.71K | 28.37% |
| 2017 | 13.80K | 78.15% |
| 2016 | 7.75K | 9.58% |
| 2015 | 7.07K | 0.00% |
| 2014 | 7.07K | 0.00% |
Uitstaande aandelen van vergelijkbare bedrijven of concurrenten
| Bedrijf | Uitstaande aandelen | Verschil | Land |
|---|---|---|---|
| 253.90M | -95.72% |
US
|
|
| 396.00M | -93.32% |
US
|
|
| 478.91M | -91.93% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -98.95% |
NL
|
